MedTrace Logo

Adult Primary Insomnia Polysomnographic Study (0928-004)(COMPLETED)

NCT00094627 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 465

Last updated 2015-01-14

No results posted yet for this study

Summary

The purpose of the study is to test the safety and effectiveness of the Investigational Drug on insomnia.

Conditions

  • Primary Insomnia

Interventions

DRUG

gaboxadol

Duration of Treatment - 6 weeks

DRUG

Comparator: placebo (unspecified)

Duration of Treatment - 6 weeks

Sponsors & Collaborators

  • H. Lundbeck A/S

    lead INDUSTRY

Principal Investigators

  • Medical Monitor · Merck Sharp & Dohme LLC

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
64 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2004-11-30
Completion
2006-04-30

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00094627 on ClinicalTrials.gov